



# Treasurer's Financial Report 2023

Mette D. Hazenberg, Treasurer EBMT

# Preface

---

Never in the nearly 50 years of EBMT's existence its financial resilience has been tested more than in the past couple of years. Major challenges to the Society imposed by the SARS-CoV-2 pandemic and the war in Ukraine were absorbed without significant impact on its financial situation. In the meantime, income continued to increase, creating opportunities for structural investments, the creation of reserves for strategic projects including the new Registry and allowing build-up of a solid buffer.



# Preface

---

In 2023 income continued to grow. The first in-person Annual Meeting in 3 years, held in Paris, was not only a scientific success. Other income was generated through the return to pre-COVID19 numbers of JACIE accreditations and through grants for studies, clinical trials and educational events.

At the same time, a number of structural investments and adjustments have been implemented as part of the 2023-2026 Strategic Plan that I would like to highlight.

# The Registry

---

One of the priorities of the 2023-2026 Strategic Plan was to replace the old IT structure of the Registry. Under the dedicated supervision of the Clinical Research and Registry Department (CRRD) and the Registry Committee a new IT system was built. After years of preparation, the new Registry was launched in August of 2023.




Costs of the development and implementation of the new Registry (excluding personnel) has been provided for through the EuroTraCTOR grant (EUR 0.6M) and earmarked reserves (EUR 2.5M).

To secure further developments (analytical tool, study modules, data migration and others) EUR 2.0M of the net result of 2023 will be appropriated to the earmarked reserves of the Registry.

# The Transplant Activity Survey

In 2023, more than 3 decades after its launch, Jakob Passweg and Helen Baldomero handed over data collection for the Transplant Activity Survey to the Business Unit (BU).

Data can now be submitted online through a new tool that was developed by the BU and collection of numbers of stem cell transplants and CAR T cell therapies performed in Europe by member and non-member centres has begun in December of 2023.



# Working Parties

---

In 2023, the fixed budget of the Working Parties (WP) was raised permanently from 16K to 26K. This was necessary to provide for the increased hours of data management support, study coordination and statistical work needed by the WP.

In addition, 1 FTE to be spent on data management and statistical support has been made available for the Haemoglobinopathies WP that was established in 2023.

All WP contribute to the Harmonisation Workshops, organised for the first time in 2023, for which funds were also made available.

# Centre Membership Fees

---

A review of the center membership model highlighted the need to update the previous approach, where reporting centers paid membership fees for benefits like event discounts and JACIE accreditation, which didn't reflect the reciprocal relationship with EBMT.

- **Proposal to the General Assembly:** Discontinue center membership fees from 2024 onwards, with 2023 being the final year of collection.
- Approved by the Board of Association in October 2023: Introduction of new membership fees effective January 2024:
  - Centers no longer charged fees for up to 10 team members + PI. Additional fee of 50€ per extra team member.
  - Reduction of physician individual fees to 90€. Other roles set at 40€.


# Investing To Secure Our Mission

---

To allow all educational, accreditation and scientific activities to grow and to increase the efficiency of EBMT and its output in all fields, structural investments have been made.

The number of FTE has grown from 101.6 in 2022 to 114.0 in 2023. These regarded positions for the Registry, JACIE, the Clinical Study Units, the Education and Events Unit, and the Executive Office (Human Resources, Finance, Legal Services, management of grants and stakeholders).

Some of these positions are covered by grants and earmarked reserves, others are covered by the increased income and free reserves.





# Final 2023 Numbers For Voting

Source of Income	EUR	%	Destination of resources	EUR	%
EBMT Members donations	626,000	2.8	Scientific Studies	5,141,000	31.9
Scientific Sponsors donations	543,000	2.5	EBMT Registry	3,213,000	19.9
Annual Meeting	7,395,000	33.6	Annual Meeting	2,937,000	18.2
Results from investments	596,000	2.7	Educational Activities	1,745,000	10.8
			Standards & Accreditation (JACIE)	993,000	6.2
<b>Non-earmarked Income</b>	<b>9,160,000</b>	<b>41.6</b>	<b>Total mission costs</b>	<b>14,029,000</b>	<b>87.1</b>
Studies, Clinical Trials & Education	11,792,000	53.6	Management and Administration	2,086,000	12.9
Accreditation (JACIE)	1,056,000	4.8			
<b>Earmarked Income</b>	<b>12,848,000</b>	<b>58.4</b>			
<b>Total Income</b>	<b>22,008,000</b>	<b>100</b>	<b>Total Expenditure</b>	<b>16,115,000</b>	<b>100</b>

# Final 2023 Numbers For Voting

---

Financial outcome	EUR	%
Total Income	22,008,000	100.0
Total Costs	16,115,000	73.2
<b>Gross Result</b>	<b>5,893,000</b>	<b>26.8</b>
Earmarked	1,255,000	5.7
<b>Net result</b>	<b>4,638,000</b>	<b>21.1</b>

# Spending On Our Mission

---



Charitywatch.org rating: A (typically, 20% of income of not-for-profit organisations is spend on overhead)

# Concluding Remarks

---

The structural investments made in the past years are paying off. With more efficient management, better IT, more personnel to handle data, studies, events, management and finances income has structurally grown.

In 2023, operating expenses expanded further to a total of **16.1M**. At the same time EBMT net income grew even more, with a non-earmarked income of **9.2M** and earmarked income of **12.8M** adding up to a total income over 2023 of **22.0M**.

The year 2023 will be closed with a net result of **5.9M**. A total of **2.0M** of this net result will be earmarked one-off to further development of the Registry as indicated above, in addition to **255K** to IT infrastructure, offices and consultancy.

# Concluding remarks

---

In addition, and in line with the 2023-2026 Strategic Plan goals, the Board approved of 1.4M to be spent in 2024 on structural investments including staff, a raise of the JACIE Inspector's per diem allowance, and IT and office infrastructural investments.

Importantly, only 13% of EBMT income is spent on governance; 87% of resources is spent on the mission goals of the Society. For reference, overhead ratios of nonprofit organisations are typically around 20%.

In conclusion, with its steady revenue growth, that covers for its steadily growing expenses, and with sufficient reserves to cover for the unexpected, EBMT continues to be a financially healthy organisation.

# Audit of EBMT's Financial Statement

---

At the time of drafting this Annual Report, we are eagerly awaiting the findings of the independent auditor. We remain confident that, consistent with previous years, EBMT will once again receive an 'unqualified opinion', affirming that our financial statements adhere to generally accepted accounting principles and accurately reflect the organisation's financial standing.

# Thanks to:

---

## Financial Team:

Bas Natkiel  
Erwin Timmers  
Sudy Anne Pourier  
Liesbeth Hoekstra  
Clara Sierra

## Executive Office:

Mirjam Steinbuch



**Thank you for your attention**

